Repeats to link to corrected alerts
Overview
Nordson Corp fiscal Q3 sales rise 12% yr/yr, beating analyst expectations, per LSEG data
Adjusted EPS for fiscal Q3 increases 13%, surpassing analyst estimates, per LSEG data
Company authorizes new $500 mln share repurchase
Outlook
Nordson expects full-year sales slightly below midpoint of original guidance
Company anticipates full-year adjusted EPS slightly above midpoint of guidance
Nordson's full-year outlook supported by pending divestiture completion
Company maintains full-year sales and earnings guidance after strong Q3
Result Drivers
ACQUISITION IMPACT - Sales growth driven by 8% favorable acquisition impact, notably from Atrion acquisition
TECHNOLOGY GROWTH - Advanced Technology Solutions segment achieved 15% organic sales growth, driven by electronics dispense product lines
MEDICAL SEGMENT - Medical and Fluid Solutions sales rose 32%, largely due to acquisition impact, with organic growth in medical fluid components
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$741.51 mln
$723.10 mln (9 Analysts)
Q3 Adjusted EPS
Beat
$2.73
$2.64 (8 Analysts)
Q3 EPS
$2.22
Q3 Net Income
$125.78 mln
Q3 Gross Margin
54.8%
Q3 Operating Profit
$187.77 mln
Q3 Pretax Profit
$159.12 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the industrial machinery & equipment peer group is "buy"
Wall Street's median 12-month price target for Nordson Corp is $249.66, about 12.9% above its August 19 closing price of $217.50
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago
Press Release: ID:nBw6bZ9Yqa
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)